Who are Unithroid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Evrenzo, MGL-3196, LT3 (liothyronine), Veligrotug (VRDN-001).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levothyroxine-sodium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Unithroid — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Unithroid (LEVOTHYROXINE SODIUM) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: l-Thyroxine. Area: Oncology.

marketed l-Thyroxine Thyroid hormone receptor beta Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Unithroid (LEVOTHYROXINE SODIUM) — Fresenius Kabi. Unithroid works by replacing or supplementing the thyroid hormone thyroxine, which is produced by the thyroid gland.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Unithroid TARGET	LEVOTHYROXINE SODIUM	Fresenius Kabi	marketed	l-Thyroxine	Thyroid hormone receptor beta	2000-01-01
Evrenzo	ROXADUSTAT	Astellas Pharma Europe B.V.	marketed		Thyroid hormone receptor beta	2021-01-01
MGL-3196	MGL-3196	Madrigal Pharmaceuticals, Inc.	phase 3	Thyroid hormone receptor beta (THR-β) selective agonist	THR-β (thyroid hormone receptor beta)
LT3 (liothyronine)	LT3 (liothyronine)	M. Medici	phase 3	Thyroid hormone replacement	Thyroid hormone receptor alpha (TRα), Thyroid hormone receptor beta (TRβ)
Veligrotug (VRDN-001)	Veligrotug (VRDN-001)	Viridian Therapeutics, Inc.	phase 3	Thyroid hormone receptor beta (THR-β) agonist	Thyroid hormone receptor beta (THR-β)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (l-Thyroxine class)

Fresenius Kabi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Unithroid — Competitive Intelligence Brief. https://druglandscape.com/ci/levothyroxine-sodium. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab